CAPR

Capricor Therapeutics, Inc. is a biotechnology company focused on the development of novel therapies for the treatment of cardiac and other serious medical conditions. Headquartered in Los Angeles, California, the company specializes in cell and exosome-based therapeutics derived from cardiac cells. Capricor's lead product candidate is CAP-1002, an allogeneic cardiac cell therapy in clinical development for the treatment of Duchenne muscular dystrophy and other indications. The therapy utilizes cardiosphere-derived cells, which are cardiac progenitor cells that have shown potential to promote tissue regeneration and reduce inflammation. The company is also advancing its exosome platform technology, which involves cell-free therapeutics that may offer advantages in manufacturing, storage, and delivery compared to whole-cell therapies. Capricor's research programs target diseases with significant unmet medical needs, including muscular dystrophies, myocarditis, and ventricular dysfunction. The company conducts clinical trials to evaluate the safety and efficacy of its product candidates and works to advance them through regulatory approval processes. Capricor collaborates with academic institutions and medical centers to further develop its innovative therapeutic approaches.